

**September 2025**

## Updated Categories for Medicare Advantage Part B Step Therapy

Florida Blue Medicare has updated its Part B Step Therapy programs. Effective **September 15, 2025**, four updated categories were added to the Part B Step Therapy program for BlueMedicare<sup>SM</sup> Medicare Advantage plans.

### Drug Alternatives

Step Therapy is required, and the definition of medical necessity must be met, for certain non-preferred medications. We encourage you to consider prescribing one of the following preferred alternatives (prior authorization may apply) instead of the non-preferred drugs.

**Note:** Additions to non-preferred products are included below in a red, bold font.

### Updates to Existing Part B Step Therapy Program Categories:

#### Autoimmune Therapy

Preferred Product		Non-preferred Products	
Tyenne	Q5135	Actemra Tofidence <b>Avtozma</b>	J3262 Q5133 <b>Q5156</b>

#### Bone Remodeling Agents

Preferred Products		Non-preferred Products	
Zoledronic acid	J3489	<b>Jubbonti</b> <b>Stoboclo</b>	<b>Q5136</b> <b>C9399, J3590</b>
Jubbonti Stoboclo	Q5136 C9399, J3590	Prolia Evenity <b>Conexence</b>	J0897 J3111 <b>J3590</b>

#### Cancer and Supportive Therapy

Preferred Products		Non-preferred Products	
Mvasi Zirabev	Q5107 Q5118	Avastin (for oncology diagnosis only) Alymsys Vegzelma Avzivi <b>Jobevne</b>	J9035 Q5126 Q5129 J3590 <b>C9399, J9999</b>
Zoledronic acid	J3489	<b>Wyost</b> <b>Osenvelt</b>	<b>Q5136</b> <b>C9399, J3590</b>
Wyost Osenvelt	Q5136 C9399, J3590	<b>Xgeva</b> <b>Bomyntra</b>	<b>J0897</b> <b>C9399, J3590</b>

## Ophthalmic Agents

Preferred Product		Non-preferred Products	
Bevacizumab	J3490 C9257	Beovu Byooviz Cimerli Eylea Eylea HD Lucentis Macugen Susvimo Vabysmo Visudyne Pavblu Enzeevu Ahzantive <b>Opuviz</b> <b>Yesafili</b>	J0179 Q5124 Q5128 J0178 J0177 J2778 J2503 J2779 J2777 J3396 Q5147 Q5149 Q5150 <b>Q5153</b> <b>Q5155</b>